Gutiérrez MJM, Jarillo LRA

Language: Spanish
References: 49
Page: 83-92
PDF size: 306.49 Kb.

ABSTRACT

The breast cancer in Mexico is the second cause of death in women aged 30 to 65, with 35 new cases / 100,000 women in this age range reported in 2019. The term «breast cancer» does not reflect a single disease; rather, it should be considered as a repertoire of diseases related to their own characteristics. In the study of breast cancer, experimental animals have been of undoubted utility. Mouse is the most widely used for several reasons, among which are the knowledge of its complete genome and being the only animal where there are efficient systems for cultivating pluripotent embryonic cells. Murine models can be classified into immunocompromised models, in which different types of mammary tumors are reproduced by implanting cancer cell lines or fragments of mammary tumors obtained of patients. The immunocompetent models, comprise strains that develop tumors through the application of carcinogens, or that do so spontaneously due to the characteristics of their native genome or by modifications thereof. Currently, there are several strains of transgenic or «knockout» mice. In this work the general characteristics of these murine models are reviewed.

REFERENCES

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144 (5): 646-674.

2. Clarke R. Animal models of breast cancer: their diversity and role in biomedical research. Breast Cancer Res Treat. 1996; 39 (1): 1-6.

3. Currier N, Solomon SE, Demicco EG, Chang DL, Farago M, Ying H et al. Oncogenic signaling pathways activated in DMBA-induced mouse mammary tumors. Toxicol Pathol. 2005; 33 (6): 726-737.

4. Abba MC, Zhong Y, Lee J, Kil H, Lu Y, Takata Y et al. DMBA induced mouse mammary tumors display high incidence of activating Pik3caH1047 and loss of function Pten mutations. Oncotarget. 2016; 7 (39): 64289-64299.

5. Lu J, Jiang C, Mitrenga T, Cutter G, Thompson HJ. Pathogenic characterization of 1-methyl-1-nitrosourea-induced mammary carcinomas in the rat. Carcinogenesis. 1998; 19 (1): 223.

6. Thompson HJ, Adlakha H. Dose-responsive induction of mammary gland carcinomas by the intraperitoneal injection of 1-methyl-1-nitrosourea. Cancer Res. 1991; 51 (13): 3411-3415.

7. Tsubura A, Lai YC, Miki H, Sasaki T, Uehara N, Yuri T et al. Review: Animal models of N-Methyl-N-nitrosourea-induced mammary cancer and retinal degeneration with special emphasis on therapeutic trials. In Vivo. 2011; 25 (1): 11-22.

8. Rehm S. Chemically induced mammary gland adenomyoepitheliomas and myoepithelial carcinomas of mice. Immunohistochemical and ultrastructural features. Am J Pathol. 1990; 136 (3): 575-384.

9. Kerdelhue B, Forest C, Coumoul X. Dimethyl-Benz(a)anthracene: A mammary carcinogen and a neuroendocrine disruptor. Biochim Open. 2016; 3: 49-55.

10. Lanari C, Lamb CA, Fabris VT, Helguero LA, Soldati R, Bottino MC et al. The MPA mouse breast cancer model: evidence for a role of progesterone receptors in breast cancer. Endocr Relat Cancer. 2009; 16 (2): 333-350.

11. Rashid OM, Takabe K. Animal models for exploring the pharmacokinetics of breast cancer therapies. Expert Opin Drug Metab Toxicol. 2015; 11 (2): 221-230.

12. Murayama T, Gotoh N. Patient-derived xenograft models of breast cancer and their application. Cells. 2019; 8 (6): 621.

13. Walsh NC, Kenney LL, Jangalwe S, Aryee KE, Greiner DL, Brehm MA et al. Humanized mouse models of clinical disease. Annu Rev Pathol. 2017; 12: 187-215.

14. Osborne CK, Hobbs K, Trent JM. Biological differences among MCF-7 human breast cancer cell lines from different laboratories. Breast Cancer Res Treat. 1987; 9 (2): 111-121.

15. Bahia H, Ashman JN, Cawkwell L, Lind M, Monson JR, Drew PJ et al. Karyotypic variation between independently cultured strains of the cell line MCF-7 identified by multicolour fluorescence in situ hybridization. Int J Oncol. 2002; 20 (3): 489-494.

16. Burdall SE, Hanby AM, Lansdown MR, Speirs V. Breast cancer cell lines: friend or foe? Breast Cancer Res. 2003; 5 (2): 89-95.

17. Ding H, Quan H, Yan W, Han J. Silencing of SOX12 by shRNA suppresses migration, invasion and proliferation of breast cancer cells. Biosci Rep. 2016; 36 (5): e00389.

18. Chavez KJ, Garimella SV, Lipkowitz S. Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer. Breast Dis. 2010; 32 (1-2): 35-48.

19. Liang Y, Benakanakere I, Besch-Williford C, Hyder RS, Ellersieck MR, Hyder SM. Synthetic progestins induce growth and metastasis of BT-474 human breast cancer xenografts in nude mice. Menopause. 2010; 17 (5): 1040-1047.

20. Dai X, Cheng H, Bai Z, Li J. Breast cancer cell line classification and its relevance with breast tumor subtyping. J Cancer. 2017; 8 (16): 3131-3141.

21. Dobrolecki LE, Airhart SD, Alferez DG, Aparicio S, Behbod F, Bentires-Alj M et al. Patient-derived xenograft (PDX) models in basic and translational breast cancer research. Cancer Metastasis Rev. 2016; 35 (4): 547-573.

22. Whittle JR, Lewis MT, Lindeman GJ, Visvader JE. Patient-derived xenograft models of breast cancer and their predictive power. Breast Cancer Res. 2015; 17: 17.

23. Garralda E, Paz K, Lopez-Casas PP, Jones S, Katz A, Kann LM et al. Integrated next-generation sequencing and avatar mouse models for personalized cancer treatment. Clin Cancer Res. 2014; 20 (9): 2476-2484.

24. Hutchinson JN, Muller WJ. Transgenic mouse models of human breast cancer. Oncogene. 2000; 19 (53): 6130-6137.

25. Hanahan D, Wagner EF, Palmiter RD. The origins of oncomice: a history of the first transgenic mice genetically engineered to develop cancer. Genes Dev. 2007; 21 (18): 2258-2270.

26. Gama Sosa MA, De Gasperi R, Elder GA. Animal transgenesis: an overview. Brain Struct Funct. 2010; 214 (2-3): 91-109.

27. Borowsky AD. Choosing a mouse model: experimental biology in context--the utility and limitations of mouse models of breast cancer. Cold Spring Harb Perspect Biol. 2011; 3 (9): a009670.

28. Menezes ME, Das SK, Emdad L, Windle JJ, Wang XY, Sarkar D et al. Genetically engineered mice as experimental tools to dissect the critical events in breast cancer. Adv Cancer Res. 2014; 121: 331-382.

29. Park JW, Neve RM, Szollosi J, Benz CC. Unraveling the biologic and clinical complexities of HER2. Clin Breast Cancer. 2008; 8 (5): 392-401.

30. Allred DC, Clark GM, Molina R, Tandon AK, Schnitt SJ, Gilchrist KW et al. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol. 1992; 23 (9): 974-979.

31. Guy CT, Cardiff RD, Muller WJ. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol. 1992; 12 (3): 954-961.

32. Guy CT, Cardiff RD, Muller WJ. Activated neu induces rapid tumor progression. J Biol Chem. 1996; 271 (13): 7673-7678.

33. Hwang TS, Han HS, Hong YC, Lee HJ, Paik NS. Prognostic value of combined analysis of cyclin D1 and estrogen receptor status in breast cancer patients. Pathol Int. 2003; 53 (2): 74-80.

34. Sutherland RL, Musgrove EA. Cyclins and breast cancer. J Mammary Gland Biol Neoplasia. 2004; 9 (1): 95-104.

35. Li Y, Hively WP, Varmus HE. Use of MMTV-Wnt-1 transgenic mice for studying the genetic basis of breast cancer. Oncogene. 2000; 19 (8): 1002-1009.

36. Deming SL, Nass SJ, Dickson RB, Trock BJ. C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance. Br J Cancer. 2000; 83 (12): 1688-1695.

37. Stewart TA, Pattengale PK, Leder P. Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes. Cell. 1984; 38 (3): 627-637.

38. Wen J, Kawamata Y, Tojo H, Tanaka S, Tachi C. Expression of whey acidic protein (WAP) genes in tissues other than the mammary gland in normal and transgenic mice expressing mWAP/hGH fusion gene. Mol Reprod Dev. 1995; 41 (4): 399-406.

39. Ozturk-Winder F, Renner M, Klein D, Muller M, Salmons B, Gunzburg WH. The murine whey acidic protein promoter directs expression to human mammary tumors after retroviral transduction. Cancer Gene Ther. 2002; 9 (5): 421-431.

40. Nielsen LL, Discafani CM, Gurnani M, Tyler RD. Histopathology of salivary and mammary gland tumors in transgenic mice expressing a human Ha-ras oncogene. Cancer Res. 1991; 51 (14): 3762-3767.

41. Green JE, Shibata MA, Yoshidome K, Liu ML, Jorcyk C, Anver MR et al. The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: ductal epithelial cell targeting with multistage progression to carcinoma. Oncogene. 2000; 19 (8): 1020-1027.

42. Yoshidome K, Shibata MA, Couldrey C, Korach KS, Green JE. Estrogen promotes mammary tumor development in C3(1)/SV40 large T-antigen transgenic mice: paradoxical loss of estrogen receptoralpha expression during tumor progression. Cancer Res. 2000; 60 (24): 6901-6910.

43. Maroulakou IG, Anver M, Garrett L, Green JE. Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. Proc Natl Acad Sci USA. 1994; 91 (23): 11236-11240.

44. Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol. 2010; 2 (1): a001008.

45. Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene. 2007; 26 (15): 2157-2165.

46. Li B, Murphy KL, Laucirica R, Kittrell F, Medina D, Rosen JM. A transgenic mouse model for mammary carcinogenesis. Oncogene. 1998; 16 (8): 997-1007.

47. Deng CX. Tumorigenesis as a consequence of genetic instability in Brca1 mutant mice. Mutat Res. 2001; 477 (1-2): 183-189.

48. Schade B, Rao T, Dourdin N, Lesurf R, Hallett M, Cardiff RD et al. PTEN deficiency in a luminal ErbB-2 mouse model results in dramatic acceleration of mammary tumorigenesis and metastasis. J Biol Chem. 2009; 284 (28): 19018-19026.

49. Deng CX. Conditional knockout mouse models of cancer. Cold Spring Harb Protoc. 2014; (12): 1217-1233.